To read the full story, subscribe or sign in.

Samsung life science fund invests $10M in C2N Diagnostics

March 14, 2025

Samsung Life Science Fund made its first strategic investment of the year into C2N Diagnostics LLC, underscoring the rising potential of blood-based diagnostics in detecting and monitoring the risk of Alzheimer’s disease for the masses.

BioWorld MedTech Financings Aging Neurology/psychiatric Diagnostics Imaging Liquid biopsy Asia-Pacific U.S.

Today's news in brief

BioWorld

BioWorld briefs for March 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 17, 2025

Clinical trial fraud ends with guilty pleas

BioWorld

In another real-life episode of “sponsor beware,” the owners of a clinical research facility pleaded guilty March 10 in U.S. district court to fraud charges...

At CROI, HIV cure trials raise hopes for broader applicability

BioWorld

At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...

Hummingbird migrates ADCs, tech to newco Callio’s $187M debut

BioWorld

Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...